Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin
Open Access
- 14 May 2020
- Vol. 11 (5), 549
- https://doi.org/10.3390/genes11050549
Abstract
Treatments that include gemcitabine and carboplatin induce dose-limiting myelosuppression. The understanding of how human bone marrow is affected on a transcriptional level leading to the development of myelosuppression is required for the implementation of personalized treatments in the future. In this study, we treated human hematopoietic stem and progenitor cells (HSPCs) harvested from a patient with chronic myelogenous leukemia (CML) with gemcitabine/carboplatin. Thereafter, scRNA-seq was performed to distinguish transcriptional effects induced by gemcitabine/carboplatin. Gene expression was calculated and evaluated among cells within and between samples compared to untreated cells. Cell cycle analysis showed that the treatments effectively decrease cell proliferation, indicated by the proportion of cells in the G2M-phase dropping from 35% in untreated cells to 14.3% in treated cells. Clustering and t-SNE showed that cells within samples and between treated and untreated samples were affected differently. Enrichment analysis of differentially expressed genes showed that the treatments influence KEGG pathways and Gene Ontologies related to myeloid cell proliferation/differentiation, immune response, cancer, and the cell cycle. The present study shows the feasibility of using scRNA-seq and chemotherapy-treated HSPCs to find genes, pathways, and biological processes affected among and between treated and untreated cells. This indicates the possible gains of using single-cell toxicity studies for personalized medicine.This publication has 32 references indexed in Scilit:
- A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivityLeukemia, 2019
- RNA sequencing reveals a transcriptomic portrait of human mesenchymal stem cells from bone marrow, adipose tissue, and palatine tonsilsScientific Reports, 2017
- Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced ToxicitiesClinical Cancer Research, 2016
- Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)Chemotherapy, 2011
- Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- The transcriptome of human CD34+hematopoietic stem-progenitor cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study GroupJournal of Clinical Oncology, 2005
- Gemcitabine: A pharmacologic and clinical overviewCancer Nursing, 1999
- Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancerAnti-Cancer Drugs, 1997
- Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IICancer Chemotherapy and Pharmacology, 1982